Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Treatment of Patients with IgA Nephropathy: Evaluation of the Safety and Efficacy of Mycophenolate Mofetil

Author(s): Zaobin Chen, Wenmin Chen, Lingqian Zheng, Yina Xie, Kaijin Yao and Tianbiao Zhou*

Volume 30, Issue 30, 2024

Published on: 10 July, 2024

Page: [2400 - 2409] Pages: 10

DOI: 10.2174/0113816128304327240620093048

Price: $65

Abstract

Introduction and Aim: Immunoglobulin A nephropathy (IgAN), characterized by aberrant IgA immune complex deposition, is the most prevalent primary glomerular disease and the main cause of end-stage renal disease, causing a significant physical and psychological burden on people worldwide. Conventional therapeutic approaches, such as renin-angiotensin-aldosterone system inhibitors and corticosteroids, may not achieve sufficient effectiveness and may produce major side events in the past. The previous data in Asian populations indicated that mycophenolate mofetil (MMF) might significantly advance the development of a new therapy strategy for IgAN. The effectiveness and safety of MMF in patients with IgAN will be investigated in this study.

Methods: A literature search was conducted on June 30th, 2023, by searching the following databases: PubMed and the Cochrane Library according to predefined criteria. To investigate the renoprotective benefits and safety of MMF, statistical analyses were performed using Cochrane’s Review Manager Version 5.3.

Results: The meta-analysis included nine randomized controlled studies that fulfilled the inclusion criterion. In the Asian population, the results revealed a substantial difference in remission rates between the MMF group and the control group (OR: 2.53, 95% CI: 1.02, 6.30, P = 0.05). MMF can increase the rate of decrease in proteinuria in IgAN patients when compared with controls in Asians (OR: 7.34, 95% CI: 2.69, 20.08, P = 0.0001), and MMF can reduce the urinary protein in patients with IgAN in Asians (WMD: -0.61, 95% CI: -1.15, -0.08, P = 0.02). Interestingly, these studies on Asians were conducted in China. However, the differences in remission rate, rate of decrease in proteinuria, and urinary protein reduction between the MMF group and control group were not found in overall populations and in the Caucasian population. The differences in complete remission rate, partial remission rate, serum creatinine (SCr) doubling rate, rate of 50% increase in SCr, and rate of need for renal replacement treatment between the MMF group and control group were not found in Asians, Caucasians, and overall populations. The difference in the rate of side effects between the MMF group and the control group was not found.

Conclusion: MMF protects renal function and is a safe medication for treating Chinese IgAN patients. MMF might significantly advance the development of a new therapy strategy for IgAN in the Chinese population.

« Previous Next »
[1]
Tian Z, Li Z, Chu L, et al. Iron metabolism and chronic inflammation in IgA nephropathy. Ren Fail 2023; 45(1): 2195012.
[http://dx.doi.org/10.1080/0886022X.2023.2195012] [PMID: 37013479]
[2]
Bechtler C, Barneoud-Rousset O, Pang L, et al. Optimized synthesis, polymer conjugation, and proof-of-concept studies of the gd-IgA1 epitope for antibody-scavenging therapies in IGA nephropathy. Chem Biol Drug Des 2023; 102(3): 580-6.
[http://dx.doi.org/10.1111/cbdd.14258] [PMID: 37186370]
[3]
Kunter U, Seikrit C, Floege J. Novel agents for treating IgA nephropathy. Curr Opin Nephrol Hypertens 2023; 32(5): 418-26.
[http://dx.doi.org/10.1097/MNH.0000000000000902] [PMID: 37382182]
[4]
Natale P, Palmer SC, Ruospo M, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2020; 3(3): CD003965.
[PMID: 32162319]
[5]
Li Y, Wan Q, Lan Z, et al. Efficacy and indications of tonsillectomy in patients with IgA nephropathy: A retrospective study. PeerJ 2022; 10: e14481.
[http://dx.doi.org/10.7717/peerj.14481] [PMID: 36523468]
[6]
Shi X, Zhou N, Zhou C, Shen Y. Clinical and pathological analysis on traditional Chinese medicine syndromes in children with immunoglobulin A nephropathy. J Tradit Chin Med 2012; 32(3): 358-63.
[http://dx.doi.org/10.1016/S0254-6272(13)60038-2] [PMID: 23297556]
[7]
Schrezenmeier E, Dörner T, Halleck F, Budde K. Cellular immunobiology and molecular mechanisms in alloimmunity-pathways of immunosuppression. Transplantation 2023; 108(1): 148-60.
[PMID: 37309030]
[8]
Cassone G, Sebastiani M, Vacchi C, Erre GL, Salvarani C, Manfredi A. Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: A narrative review. Drugs Context 2021; 10: 1-17.
[http://dx.doi.org/10.7573/dic.2020-8-8] [PMID: 33505480]
[9]
Si R, Zhao P, Yu Z, et al. Increased non-switched memory B cells are associated with plasmablasts, serum IL-6 levels and renal functional impairments in IgAN patients. Immunol Invest 2020; 49(1-2): 178-90.
[http://dx.doi.org/10.1080/08820139.2019.1683026] [PMID: 31670996]
[10]
Shen BL, Qu QS, Miao SZ, Liu BL, Liu RY, Gu DF. Study on the effects of regulatory T cells on renal function of IgAN rat model. Eur Rev Med Pharmacol Sci 2015; 19(2): 284-8.
[PMID: 25683943]
[11]
Hou FF, Xie D, Wang J, et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy. JAMA Netw Open 2023; 6(2): e2254054.
[http://dx.doi.org/10.1001/jamanetworkopen.2022.54054] [PMID: 36745456]
[12]
Liu X, Dewei D, Sun S, et al. Treatment of severe IgA nephropathy: Mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone. Int J Clin Pharmacol Ther 2014; 52(2): 95-102.
[http://dx.doi.org/10.5414/CP201887] [PMID: 24161158]
[13]
Tang S, Leung JCK, Chan LYY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68(2): 802-12.
[http://dx.doi.org/10.1111/j.1523-1755.2005.00460.x] [PMID: 16014059]
[14]
Rovin BH, Adler SG, Barratt J, et al. Kidney disease: Improving global outcomes (KDIGO) glomerular diseases work group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 2021; 100(4S): S1-S276.
[PMID: 34556256]
[15]
Hou JH, Le WB, Chen N, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: A randomized controlled trial. Am J Kidney Dis 2017; 69(6): 788-95.
[http://dx.doi.org/10.1053/j.ajkd.2016.11.027] [PMID: 28215945]
[16]
Hogg RJ, Bay RC, Jennette JC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 2015; 66(5): 783-91.
[http://dx.doi.org/10.1053/j.ajkd.2015.06.013] [PMID: 26209543]
[17]
Liu XW, Li DM, Xu GS, Sun SR. Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. Int J Clin Pharmacol Ther 2010; 48(8): 509-13.
[http://dx.doi.org/10.5414/CPP48509] [PMID: 20650041]
[18]
Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs. placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20(10): 2139-45.
[http://dx.doi.org/10.1093/ndt/gfh974] [PMID: 16030050]
[19]
Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65(5): 1842-9.
[http://dx.doi.org/10.1111/j.1523-1755.2004.00588.x] [PMID: 15086925]
[20]
Chen X, Chen P, Cai G, et al. A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi 2002; 82(12): 796-801.
[PMID: 12126522]
[21]
Xu G, Tu W, Jiang D, Xu C. Mycophenolate mofetil treatment for IgA nephropathy: A meta-analysis. Am J Nephrol 2009; 29(5): 362-7.
[http://dx.doi.org/10.1159/000168483] [PMID: 18974636]
[22]
Du B, Jia Y, Zhou W, Min X, Miao L, Cui W. Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: An update meta-analysis. BMC Nephrol 2017; 18(1): 245.
[http://dx.doi.org/10.1186/s12882-017-0647-x] [PMID: 28724421]
[23]
Zheng JN, Bi TD, Zhu LB, Liu LL. Efficacy and safety of mycophenolate mofetil for IgA nephropathy: An updated meta-analysis of randomized controlled trials. Exp Ther Med 2018; 16(3): 1882-90.
[http://dx.doi.org/10.3892/etm.2018.6418] [PMID: 30186414]
[24]
Peng XJ, Zheng WM, Fu R, et al. Efficacy and safety of mycophenolate mofetil in the treatment for IgA nephropathy: A meta-analysis of randomized controlled trials. Clin Exp Nephrol 2021; 25(7): 788-801.
[http://dx.doi.org/10.1007/s10157-021-02028-5] [PMID: 33710500]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy